YOLFTbeta
CMG Pharmaceutical Co. Ltd

CMG Pharmaceutical Co. Ltd

058820 · KQ · Healthcare / Drug Manufacturers - Specialty & Generic

3,840.00KRW+40.00 (+1.05%)

Price History

Full chart

Market Stats

Previous Close3,800.00
Open3,815.00
Day Range3,810.00 – 3,935.00
52-Week Range526.00 – 2,205.00
Volume35.54K
Market Cap83.25B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.44
50-Day Avg627.82
200-Day Avg1,353.35

About

CMG Pharmaceutical Co., Ltd., a pharmaceutical company, develops and sells oral thin film (OTF) pharmaceuticals in South Korea. It offers Tadalafil OTF products for erectile dysfunction; Entecavir OTF products to treat hepatitis type B; Aripiprazole OTF products for schizophrenia; and Montelukast OTF products to treat asthma and allergic rhinitis. CMG Pharmaceutical Co. Ltd. has a strategic collaboration agreement with Handok Inc. for cancer treatment. The company was formerly known as Skynewpharm Co Ltd and changed its name to CMG Pharmaceutical CO., Ltd. in April 2013. CMG Pharmaceutical Co., Ltd. was founded in 2001 and is headquartered in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOJoohyung Lee
  • Employees242
  • HeadquartersCheongdam-dong 18-20, #B01, Seoul, South Korea, 135-949, Korea
  • Websitehttps://www.cmgpharma.co.kr

Leadership

  • Joohyung LeeChief Executive Officer
  • Joong-Hwan BaeHead of Management Supporting Team and Director · b. 1954
  • Hyeongnam KimManaging Director

Financials

Income Statement

Currency: KRW2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue17.75B16.26B20.40B22.75B27.04B32.97B41.54B49.86B58.62B64.46B69.48B82.20B93.91B99.10B105.23B
Growth (%)--8.43%+25.51%+11.52%+18.85%+21.92%+25.98%+20.05%+17.56%+9.96%+7.78%+18.31%+14.25%+5.53%+6.19%
Cost of Revenue9.50B10.78B11.57B13.11B17.24B19.66B23.50B27.12B29.70B33.25B36.02B41.30B50.20B53.38B44.30B
Gross Profit---8.39B9.80B13.31B18.04B22.74B28.92B31.21B33.45B40.90B43.70B45.72B60.93B
Gross Margin---36.86%36.26%40.36%43.43%45.60%49.34%48.42%48.15%49.76%46.54%46.14%57.91%
Operating Expense---7.94B13.66B11.67B16.50B20.29B26.41B30.66B30.25B38.25B36.60B43.21B64.63B
Operating Income623.82M-791.25M442.32M-3.86B1.64B1.54B2.45B2.51B554.22M3.20B2.65B7.10B2.51B-3.69B
Operating Margin3.51%-3.88%1.94%-14.27%4.97%3.71%4.92%4.29%0.86%4.61%3.23%7.56%2.53%-3.51%
EBITDA-----------1.04B9.37B8.74B-5.59B
EBITDA Margin-----------1.27%9.98%8.82%-5.31%
Net Income--296.18M158.04M-3.65B1.73B2.83B6.07B3.05B215.00M3.17B-388.14M6.46B2.69B-10.08B
Net Income Margin--1.45%0.69%-13.50%5.24%6.83%12.16%5.20%0.33%4.56%-0.47%6.87%2.72%-9.58%
R&D23.70M-5.14B116.53M831.91M1.41B1.80B777.80M2.12B3.09B3.41B3.31B2.18B1.45B1.07B
R&D as % of Total Revenue0.13%-25.21%0.51%3.08%4.28%4.32%1.56%3.62%4.79%4.91%4.03%2.32%1.47%1.02%
Interest Expense0000000011.05M22.85M21.01M15.28M79.54M2.51B3.17B
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.02%0.04%0.03%0.02%0.08%2.53%3.01%

Balance Sheet

Currency: KRW2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets27.31B57.11B55.91B58.07B56.53B110.98B109.57B114.38B192.24B195.36B199.17B213.26B242.10B303.44B305.96B
Total Liabilities9.27B25.52B6.92B9.07B9.73B9.87B11.62B10.40B12.08B14.22B14.47B28.31B51.87B113.89B104.41B
Total Equity18.03B31.59B49.00B49.00B46.81B101.11B97.94B103.98B180.16B181.13B184.70B184.95B190.23B189.54B201.55B
Cash1.15B4.67B21.71B8.83B2.57B2.15B3.80B13.46B18.57B8.04B4.76B4.46B1.24B2.59B6.12B
Total Debt--------156.76M69.18M-----
Net Debt-----------1.54B24.34B76.92B65.60B

Cash Flow

Currency: KRW2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow---724.89M2.41B2.31B1.95B886.78M2.82B2.94B5.63B4.94B3.91B290.09M-11.02B
Investing Cash Flow--21.14B-13.61B-8.67B-55.08B-467.12M8.78B-70.60B-13.01B-8.48B-10.87B-28.22B-55.74B-
Financing Cash Flow3.04B35.36B-5.45M52.36B52.36B171.18M72.88B72.88B-461.47M-483.84M5.63B21.10B56.78B-
Capital Expenditure375.00M571.10M2.73B9.42B3.64B799.00M760.59M2.55B8.18B9.65B3.95B10.31B15.25B31.75B33.01B
Free Cash Flow---------9.41B-6.71B1.68B-5.37B-11.34B-31.46B-44.03B
FCF to OCF---------333.30%-227.77%29.80%-108.76%-290.01%-10843.98%399.57%

Earnings

Report DateMar 31, 2009Jun 30, 2009Sep 30, 2009Dec 31, 2009Mar 31, 2010Jun 30, 2010Sep 30, 2010Dec 31, 2010Mar 31, 2011Jun 30, 2011Sep 30, 2011Dec 31, 2011Mar 31, 2012Jun 30, 2012Sep 30, 2012Dec 31, 2012Mar 31, 2013Jun 30, 2013Sep 30, 2013Dec 31, 2013Mar 31, 2014Aug 14, 2014Nov 14, 2014Feb 24, 2015May 17, 2015Aug 17, 2015Nov 17, 2015Feb 25, 2016May 16, 2016Aug 16, 2016Oct 27, 2016Feb 8, 2017May 15, 2017Aug 10, 2017Nov 13, 2017Mar 8, 2018May 14, 2018Aug 14, 2018Nov 13, 2018Feb 19, 2019May 15, 2019Aug 14, 2019Nov 13, 2019Feb 13, 2020May 15, 2020Aug 14, 2020Nov 12, 2020Mar 18, 2021Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Mar 29, 2024Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate----------------------------------------------------------------------
EPS Actual-95.27-214.40-110.44-587.19-86.48-133.671.12-129.931.597.880.49-41.630.50-51.23-13.51-63.261.803.721.61-3.454.030.74-2.06-1.061.91-6.98-2.01-28.752.003.385.475.413.8710.157.70-23.308.2312.23-3.2734.704.519.749.552.5610.036.004.00-17.709.31-0.4812.691.281.36-0.2632.45-36.3518.4825.3618.57-19.0615.3641.02-19.30-20.50-11.39-76.4038.84-22.540.7814.41
Surprise----------------------------------------------------------------------
Timing---------------------Pre-marketAfter-hoursPre-marketAfter-hoursPre-marketPre-marketPre-market-Pre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursPre-market-Pre-marketAfter-hoursPre-marketPre-market-Pre-marketPre-market-----------Pre-market----------

Key Statistics & Ratios

Market Cap83.25B
Enterprise Value132.51B
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.72
Price / Book0.40
Revenue (TTM)115.71B
Gross Profit (TTM)64.48B
EBITDA-943.66M
Profit Margin4.01%
Operating Margin-10.44%
Return on Equity2.31%
Return on Assets-0.72%
Shares Outstanding148.12M
Shares Float110.25M
Beta0.44
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Oct 27, 20261:10
  • Jun 13, 20191709:1592
  • Sep 26, 2016754:701
  • Aug 28, 20072:1
  • Feb 13, 2007550:497
  • Jul 31, 20061:3